ArticleClinical epigenetics2026
Circulating tumor DNA methylation-based method for noninvasive detection and stage stratification of colorectal tumor.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Carbohydrate antigen 72-4 and tumor-associated glycoprotein 72 - tumor marker: Past, present and future.World journal of gastrointestinal pathophysiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundEarly detection and optimal treatment could improve the outcomes of patients with colorectal cancer (CRC). No adequate method has been developed to meet these two requirements. Here, we aimed to identify differential circulating tumor DNA (ctDNA) methylation biomarkers associated with CRC, and then establish models for detection, stage stratification and clinical decision-making.
resultsA total of 636 participants were included in this prospective study. To identify differential ctDNA methylation biomarkers, we first performed a genome-wide analysis between tumor and adjacent normal tissues using the α-value, which is sensitivity to ctDNA methylation signals. After filtering with PBMC samples, 4965 biomarkers were identified. A panel of 21 biomarkers was selected after shrinkage. A ctDNA methylation-based CRC diagnostic model (cMCD) was constructed. The cMCD yielded a sensitivity of 87.82% (83.39%-91.41%) for the combined detection of advanced adenomas and CRC, and a specificity of 91.88% (88.54%-94.49%). The overall accuracy was 89.85% (87.50%-92.30%), which was much greater than that of tumor markers [CEA: 67.30% (63.50%-70.93%); CA19-9: 59.91% (55.98%-63.74%); CA72-4: 55.66% (51.70%-59.57%); all P < 0.001]. As the risk score and sensitivity of the cMCD tended to increase with tumor progression, we constructed another ctDNA methylation-based model to stratify stage (cMCSS) and further guide treatment selection, specifically for discriminating the Early-stage patients eligible for curative endoscopic resection and avoiding overtreatment. The cMCSS could discriminate 75.86% (68.81%-82.02%) of Early-stage patients (advanced adenomas and T1N0M0 CRCs), for whom endoscopic resection could achieve curative intent, and 89.45% (84.59%-93.19%) of Advanced-stage patients. The accuracy [83.42% (79.36%-86.96%)] was significantly greater than that of tumor markers [CEA: 60.20% (55.17%-65.08%); CA19-9: 51.77% (46.71%-56.83%); CA724: 46.17% (41.16%-51.25%); all P < 0.001].
conclusionsThe approach based on ctDNA methylation is a noninvasive and robust method for both early detection and tumor stratification of CRC and could benefit patients in clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.